Four major factors regulate phosphatidylinositol 3-kinase signaling pathway in cancers induced by infection of human papillomaviruses

Current Medicinal Chemistry

Volumn 21, Issue 26, 2014, Pages 3057-3069

  Wu, Jianghong ^a,b   Chen, Jiezhong ^c   Zhang, Lifang ^d   Masci, Paul P ^c   Zhao, Kong Nan ^c,d  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

AKT; Growth factor receptor; Human papillomavirus; Mammalian target of rapamycin (mTOR); Notch receptor; Phosphatidylinositol 3 kinase (PI3K); PI3KCAgene; Rasgene

Indexed keywords

GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN;

CARCINOGENICITY; CELL IMMORTALIZATION; EPITHELIUM CELL; HUMAN; NEOPLASM; NONHUMAN; ONCOGENE RAS; PAPILLOMAVIRUS INFECTION; PHENOTYPE; PI3KCA GENE; REVIEW; SIGNAL TRANSDUCTION; TUMOR GENE; ANIMAL; CELL PROLIFERATION; COMPLICATION; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; CELL PROLIFERATION; HUMANS; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84906077492     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140414101528     Document Type: Review

References (120)

1. Zhao, K.N.; Chen, J. Codon usage roles in human papillomavirus. Rev. Med. Virol., 2011, 21(6), 397-411.
2. Talora, C; Cialfi, S.; Segatto, O.; Morrone, S.; Kim Choi, J.; Frati, L.; Paolo Dotto, G.; Gulino, A.; Screpanti, I. Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways. Exp. Cell Res., 2005, 305(2), 343-354.
3. zur Hausen, H. Viruses in human cancers. Science, 1991, 254 (5035), 1167-1173.
4. Dolma, S.; Lessnick, S. L.;Hahn, W. C; stockwell, B.R. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell, 2003, 3(3), 285-296.
5. Jayshree, R.S.; Sreenivas, A.; Tessy, M.; Krishna, S. Cell intrinsic &extrinsic factors in cervical carcinogenesis. Indian J.Med. Res., 2009, 130(3), 286-295.
6. Whelan, R.D.; Kiley, S.C.; Parker, P.J. Tetradecanoyl phorbol acetate-induced microtubule reorganization is required for sustained mitogen-activated protein kinase activation and morphological differentiation of U937 cells.Cell Growth Differ., 1999, 10(4), 271-277.
7. Patel, H., Polanco-Echeverry, G.; Volikos, E.; Segditsas, S.; McCart, A.; Lai, C.; Guenther, T.; Zaitoun, A.; Sieber, O.; Ilyas, M.; Northover, J.; Silver, A. Activation of AKT and nuclear accumulation of wild type TP53 and MDM2 in anal squamous cell carcinoma. International journal of cancer. J. Internatl du Cancer, 2007, 121(12), 2668-2673.
8. Wierzbicka, M.; Jozefiak, A.; Szydlowski, J.; Marszalek, A.; Stankiewicz, C.; Hassman-Poznanska, E.; Osuch-Wojcikiewicz, E.; Skladzien, J.; Klatka, J.; Pietruszewska, W.; Puacz, E.; Szyfter, K.; Szyfter, W. Recommendations for the diagnosis of human papilloma virus (HPV) high and low risk in the prevention and treatment of diseases of the oral cavity, pharynx and larynx. Guide of experts PTORL and KIDL.Otolaryngol. Pol., 2013, 67(3), 113-134.
9. Sichtig, N.; Silling, S.; Steger, G. Papillomavirus binding factor (PBF)-mediated inhibition of cell growth is regulated by 14-3-3beta. Arch. Biochem. Biophys., 2007, 464(1), 90-99.
10. Schiller, J.T.;Lowy, D.R. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat. Rev. Microbiol., 2012, 10(10), 681-692.
11. Stoler, M.H.; Rhodes, C.R.; Whitbeck, A.; Wolinsky, S.M.; Chow, L.T.; Broker, T.R. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol., 1992, 23(2), 117-128.
12. Fang, N.X.; Gu, W.; Ding, J.; Saunders, N.A.; Frazer, I.H.; Zhao, K.N. Calcium enhances mouse keratinocyte differentiation in vitro to differentially regulate expression of papillomavirus authentic and codon modified L1 genes. Virology, 2007, 365(1), 187-197.
13. Gu, W.; Ding,J.; Wang, X.; de Kluyver, R.L.; Saunders, N.A.; Frazer, I.H.; Zhao, K.N. Generalized substitution of isoencoding codons shortens the duration of papillomavirus L1 protein expression in transiently gene-transfected keratinocytes due to cell differentiation. Nucleic Acids Res., 2007, 35(14), 4820-4832.
14. Zhao, K.N.; Gu, W.; Fang, N.X.; Saunders, N.A.; Frazer, I.H. Gene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo.Mol Cell Biol., 2005, 25(19), 8643-8655.
15. Van Doorslaer, K.; Burk, R.D. Evolution of human papillomavirus carcinogenicity. Adv. Virus Res., 2010, 77, 41-62.
16. Durst, M.; Croce, C.M.; Gissmann, L.; Schwarz, E.; Huebner, K. Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas. Proc. Natl. Acad. Sci. USA, 1987, 84 (4),1070-1074.
17. Romanczuk, H.; Villa, L.L.; Schlegel, R.; Howley, P.M. The viral transcriptional regulatory region upstream of the E6 and E7 genes is a major determinant of the differential immortalization activities of human papillomavirus types 16 and 18.J Virol., 1991, 65(5), 2739-2744.
18. Crook, T.; Morgenstern, J.P. ; Crawford, L.; Banks, L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJras. EMBO J., 1989, 8(2), 513-519.
19. Gripp, K.W., Bifeld, E.; Stabley, D.L.; Hopkins, E.; Meien, S.; Vinette, K.; Sol-Church, K.; Rosenberger, G. A novel HRAS substitution (c.266CG; p.S89C) resulting in decreased downstream signaling suggests a new dimension of RAS pathway dysregulation in human development. Am. J. Med. Genet. A., 2012, 158A(9), 2106-2118.
20. Nees, M., Geoghegan, J.M.; Hyman, T.; Frank, S.; Miller, L.; Woodworth, C.D. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol., 2001, 75(9), 4283-4296.
21. McAuliffe, P.F.; Meric-Bernstam, F.; Mills, G.B.; Gonzalez-Angulo, A.M. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin. Breast Cancer, 2010, 10 Suppl 3, S59-S65.
22. Surviladze, Z.; Dziduszko, A.; Ozbun, M.A. Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathogens, 2012, 8(2), e1002519.
23. Schiller, J.T.; Day, P.M.; Kines, R.C. Current understanding of the mechanism of HPV infection. Gynecol. Oncol., 2010, 118(1 Suppl), S12-S17.
24. Liu, W.J.; Qi, Y.M.; Zhao, K.N.; Liu, Y.H.; Liu, X.S.; Frazer, I.H. Association of bovine papillomavirus type 1 with microtubules. Virology, 2001, 282(2), 237-244.
25. Eijsink, J.J.; Noordhuis, M.G.; ten, Hoor, K.A.; Kok, M.; Hollema, H.; de, Bock G.H.; Nijman, H.W.; Schuuring, E.; Wisman, G.B.; van, der Zee A. G.The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer. Human Pathol., 2010, 41(12), 1735-1741.
26. Yu, J.J.; Yu, J.J.; Fu, P.; Pink, J.J.; Dawson, D.; Wasman, J.; Orem, J.; Mwanda, W.O.; Zhu, H.; Liang, X.; Guo, Y.; Petros, W.P.; Mitsuyasu, R.T.; Wabinga H.; Remick S. C. HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinoma. PloS One, 2010, 5(5), e10477.
27. Jost, M.; Kari, C.; Rodeck, U. The EGF receptor-an essential regulator of multiple epidermal functions. Eur. J. Dermatol., 2000, 10(7), 505-510.
28. Jost, M.; Huggett, T.M.;Kari, C.;Boise, L. H.;Rodeck, U. Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway. J. Biol. Chem., 2001, 276(9), 6320-6326.
29. Hansen, L.A.; Woodson, R
30. Sibilia, M.; Fleischmann, A.; Behrens, A.; Stingl, L.; Carroll, J.; Watt, F.M.; Schlessinger, J.; Wagner, E.F. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell, 2000, 102(2), 211-220.
31. Stankiewicz, E.; Prowse, D.M.; Ng, M.; Cuzick, J.; Mesher, D.; Hiscock, F.; Lu, Y.J.; Watkin, N.; Corbishley, C.; Lam W.; Berney D.M. Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas. PloS One, 2011, 6(3), e17517.
32. Gupta, A.K.; Lee, J.H.; Wilke, W.W.; Quon, H.; Smith, G.; Maity, A.; Buatti, J.M.; Spitz, D.R. Radiation response in two HPVinfected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT. Int. J. Radiat. Oncol. Biol. Phys., 2009, 74(3), 928-933.
33. Joyce, J.A.; Baruch, A.; Chehade, K.; Meyer-Morse, N.; Giraudo, E.; Tsai, F.Y.; Greenbaum, D.C.; Hager, J.H.; Bogyo M.; Hanahan, D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell, 2004, 5(5), 443-453.
34. Dennemarker, J.; Lohmuller, T.; Mayerle, J.; Tacke, M.; Lerch, M.M.; Coussens, L.M.; Peters, C.Reinheckel, T. Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis. Oncogene, 2010, 29(11), 1611-1621.
35. Straight, S.W.; Hinkle, P.M.; Jewers, R.J.; McCance, D.J. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J. Virol., 1993, 67(8), 4521-4532.
36. Crusius, K.; Auvinen, E.; Steuer, B.; Gaissert, H.; Alonso, A. The human papillomavirus type 16 E5-protein modulates liganddependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Exp. Cell Res., 1998, 241(1), 76-83.
37. Pim, D.; Collins, M.; Banks, L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene, 1992, 7(1), 27-32.
38. Zhang, B.; Spandau, D.F.; Roman, A. E5 protein of human papillomavirus type 16 protects human foreskin keratinocytes from UV B-irradiation-induced apoptosis. J. Virol., 2002, 76(1), 220-231.
39. Leechanachai, P.; Banks, L.; Moreau, F.; Matlashewski, G. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene, 1992, 7(1), 19-25.
40. Kim, S.H.; Juhnn, S.Y.; Kang, S.; Park, S.W.; Sung, M.W.; Bang Y.J.; Song, Y.S. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ ERK1,2 and PI3K/Akt. Cell. Mol. Life Sci., 2006, 63(7-8), 930-938.
41. Crusius, K.; Auvinen, E.; Alonso, A. Enhancement of EGF-and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein.Oncogene, 1997, 15(12),1437-1444.
42. Petti, L.M.; Ricciardi, E.C.; Page H.J.; Porter, K.A. Transforming signals resulting from sustained activation of the PDGFbeta receptor in mortal human fibroblasts. J. Cell. Sci., 2008, 121(Pt 8), 1172-1182.
43. Surviladze, Z.; Sterk, R.T.; DeHaro, S.A.; Ozbun, M.A. Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy. J. Virol., 2013, 87(5), 2508-2517.
44. Donald, C.D.; Cooper, C.R.; Harris-Hooker, S.; Emmett, N.; Scanlon, M.; Cooke, D.B., 3rd. Cytoskeletal organization and cell motility correlates with metastatic potential and state of differentiation in prostate cancer. Cell. Mol. Biol. (Noisy-le-grand), 2001, 47(6),1033-1038.
45. Feng, W.; Duan, X.; Liu, J.; Xiao, J.; Brown, R.E. Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int. J. Clin. Exp. Pathol., 2009, 2(3), 249-260.
46. Dackour, R.; Carter, T.; Steinberg, B.M. Phosphatidylinositol 3-kinase regulates early differentiation in human laryngeal keratinocytes. In vitro Cell. Devel. Biol. Anim., 2005, 41(3-4), 111-117.
47. Gottlieb, A.B.; Chang, C. K.; Posnett, D. N.; Fanelli, B.; Tam, J.P. Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes. J. Exp. Med., 1988, 167(2), 670-675.
48. Zhang, P.; Steinberg, B.M. Overexpression of PTEN/MMAC1 and decreased activation of Akt in human papillomavirus-infected laryngeal papillomas. Cancer Res., 2000, 60(5), 1457-1462.
49. Dominey, A.M.; Wang, X. J.; King, L.E.; Nanney, L.B.;Gagne, T.A.; Sellheyer, K.;Bundman, D. S.; Longley, M.A.; Rothnagel, J.A.; Greenhalgh, D. A.Targeted overexpression of transforming growth factor alpha in the epidermis of transgenic mice elicits hyperplasia, hyperkeratosis, and spontaneous, squamous papillomas. Cell Growth Differ., 1993, 4(12), 1071-1082.
50. Serewko, M.M.,Popa, C.; Dahler, A. L.; Smith, L.; Strutton, G. M.; Coman, W.; Dicker, A. J.; Saunders, N. A. Alterations in gene expression and activity during squamous cell carcinoma development.Cancer Res., 2002, 62(13), 3759-3765.
51. Talora, C.; Cialfi, S.; Oliviero, C.; Palermo, R.; Pascucci, M.; Frati, L.; Vacca, A.; Gulino, A.; Screpanti, I. Cross talk among Notch3, pre-TCR, and Tal1 in T-cell development and leukemogenesis. Blood, 2006, 107(8), 3313-3320.
52. Keysar, S.B.; Astling, D.P.; Anderson, R.T.; Vogler, B.W.; Bowles, D.W.; Morton, J.J.; Paylor, J.J.; Glogowska, M.J.; Le, P.N.; Eagles-Soukup, J.R.; Kako, S.L.; Takimoto, S.M.; Sehrt, D.B.; Umpierrez, A.; Pittman, M.A.; Macfadden, S.M.; Helber, R.M.; Peterson, S.; Hausman, D.F.; Said, S.; Leem, T.H.; Goddard, J.A.; Arcaroli, J.J.; Messersmith, W.A.; Robinson, W.A.; Hirsch, F.R.; Varella-Garcia, M.; Raben, D.; Wang, X.J.; Song, J.I.; Tan A.C.; Jimeno, A. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol. Oncol., 2013, 7(4), 776-790.
53. Moriuchi, H.; MoriuchiM. ; Fauci, A.S. Cloning and analysis of the promoter region of CCR5, a coreceptor for HIV-1 entry. J. Immunol., 1997, 159(11), 5441-5449.
54. Majka, M.; Drukala, J.; Lesko, E.; Wysoczynski, M.; Jenson, A.B.; Ratajczak, M.Z. SDF-1 alone and in co-operation with HGF regulates biology of human cervical carcinoma cells. Folia Histochem. Cytobiol., 2006, 44(3), 155-164.
55. Yang, Y.C.; Lee, Z.Y.; Wu, C.C.; Chen, T.C.; Chang C.L.; Chen C.P. CXCR4 expression is associated with pelvic lymph node metastasis in cervical adenocarcinoma. Int. J. Gynecol. Cancer, 2007, 17(3), 676-686.
56. Gentilini, A.; Rombouts, K.; Galastri, S.; Caligiuri, A.; Mingarelli, E.; Mello, T.; Marra, F.; Mantero, S.; Roncalli, M.; Invernizzi, P.; Pinzani, M. Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. J. Hepatol., 2012, 57(4), 813-820.
57. Chow, K.Y.; Brotin, E.; Ben, K.Y.; Carthagena, L.; Teissier, S.; Danckaert, A.; Galzi, J.L.; Arenzana-Seisdedos, F.; Thierry, F.; Bachelerie, F. A pivotal role for CXCL12 signaling in HPVmediated transformation of keratinocytes: clues to understanding HPV-pathogenesis in WHIM syndrome.Cell Host Microbe., 2010, 8(6), 523-533.
58. Oh, J.M.; Kim, S.H.; Lee, Y.I.; Seo, M.; Kim, S.Y.; Song, Y.S.; Kim W.H.; Juhnn Y.S. Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells.Carcinogenesis, 2009, 30(1), 141-149.
59. Ganguly, N. Human papillomavirus-16 E5 protein: oncogenic role and therapeutic value.Cell. Oncol., 2012, 35(2), 67-76.
60. Kim, M.K.; Kim, H.S.; Kim, S.H.; Oh, J.M.; Han, J.Y.; Lim, J.M.; Juhnn Y.S.; Song Y.S. Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment. Biochem. Pharmacol., 2010, 80(12), 1930-1935.
61. Shen, M.R.; Lin, A.C.; Hsu, Y.M.; Chang, T.J.; Tang, M.J.; Alper, S.L.; Ellory J.C.; Chou C.Y. Insulin-like growth factor 1 stimulates KCl cotransport, which is necessary for invasion and proliferation of cervical cancer and ovarian cancer cells. J. Biol. Chem., 2004, 279(38), 40017-40025.
62. Huang, Y.F.; Shen, M.R.; Hsu, K.F.; Cheng Y.M.; Chou C.Y. Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer. Br. J. Cancer, 2008, 99(7),1096-1102.
63. Serrano, M.L.; Sanchez-Gomez, M.; Bravo, M.M.; Yakar, S.; LeRoith, D. Differential expression of IGF-I and insulin receptor isoforms in HPV positive and negative human cervical cancer cell lines. Horm. Metab. Res., 2008, 40(10), 661-667.
64. Chen, R.J.; Chen, S.U.; Chou, C.H.; Lin, M.C. Lysophosphatidic acid receptor 2/3-mediated IL-8-dependent angiogenesis in cervical cancer cells. Int. J. Cancer, 2011, 131(4), 789-802.
65. Oh, J.M.; Kim, S.H.; Lee, Y.I.; Seo, M.; Kim, S.Y.; Song, Y.S.; Kim W.H.; Juhnn,Y.S. Human papillomavirus type 16 E5 protein inhibits hydrogen-peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in human cervical cancer cells.Carcinogenesis, 2010, 31(3), 402-410.
66. Peyssonnaux, C.; Provot, S.; Felder-Schmittbuhl, M.P.; Calothy G.; Eychene, A. Induction of postmitotic neuroretina cell proliferation by distinct Ras downstream signaling pathways. Mol. Cell Biol., 2000, 20(19), 7068-7079.
67. Anderson, J. A.; Irish, J.C.; McLachlin, C.M.; Ngan, B.Y. H-ras oncogene mutation and human papillomavirus infection in oral carcinomas. Arch. Otolaryngol. Head Neck Surg., 1994, 120(7), 755-760.
68. Fothergill, T.; McMillan, N.A. Papillomavirus virus-like particles activate the PI3-kinase pathway via alpha-6 beta-4 integrin upon binding. Virology, 2006, 352(2), 319-328.
69. Cordova-Alarcon, E.; Centeno, F.; Reyes-Esparza, J.; Garcia-Carranca A.; Garrido, E. Effects of HRAS oncogene on cell cycle progression in a cervical cancer-derived cell line. Arch. Med. Res., 2005, 36(4), 311-316.
70. Narisawa-Saito, M.; Yoshimatsu, Y.; Ohno, S.; Yugawa, T.; Egawa, N.; Fujita, M.; Hirohashi, S.; Kiyono, T. An in vitro multistep carcinogenesis model for human cervical cancer. Cancer Res., 2008, 68(14), 5699-5705.
71. Liu, B.; Xia, X.; Zhu, F.; Park, E.; Carbajal, S.; Kiguchi, K.; Di Giovanni, J.; Fischer, S. M.; Hu, Y. IKKalpha is required to maintain skin homeostasis and prevent skin cancer. Cancer Cell, 2008, 14(3), 212-225.
72. Castellano, E.; Downward, J. Role of RAS in the regulation of PI 3-kinase. Curr. Top. Microbiol. Immunol., 2010, 346, 143-169.
73. Groesser, L.; Herschberger, E.; Ruetten, A.; Ruivenkamp, C.; Lopriore, E.; Zutt, M.; Langmann, T.; Singer, S.; Klingseisen, L.; Schneider-Brachert, W.; Toll, A.; Real, F. X.; Landthaler, M.; Hafner, C.Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat. Genet., 2012, 44(7), 783-787.
74. Campbell, P.M.; Groehler, A.L.; Lee, K.M.; Ouellette, M.M.; Khazak,V.; Der, C.J. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res., 2007, 67(5), 2098-2106.
75. Narisawa-Saito, M.; Inagawa, Y.; Yoshimatsu, Y.; Haga, K.; Tanaka, K.; Egawa, N.; Ohno, S.; Ichikawa, H.; Yugawa, T.; Fujita, M.; Kiyono, T. A critical role of MYC for transformation of human cells by HPV16 E6E7 and oncogenic HRAS. Carcinogenesis, 2012, 33(4), 910-917.
76. Cheng, G.; Meinkoth, J.L. Enhanced sensitivity to apoptosis in Ras-transformed thyroid cells. Oncogene, 2001, 20(50), 7334-7341.
77. Ramirez, de Molina A.; Sarmentero-Estrada, J.; Belda-Iniesta, C.; Taron, M.; Ramirez, de Molina V.; Cejas, P.; Skrzypski, M.; Gallego-Ortega, D.; de Castro, J.; Casado, E.; Garcia-Cabezas, M. A.; Sanchez, J. J.; Nistal, M.; Rosell, R.; Gonzalez-Baron, M.; Lacal, J. C. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K.Oncogene, 2002, 21(6), 937-946.
78. Yugawa, T., Yugawa, T.; Handa, K.; Narisawa-Saito, M.; Ohno, S.; Fujita, M.; Kiyono, T. Regulation of Notch1 gene expression by p53 in epithelial cells. Mol. Cell. Biol., 2007, 27(10), 3732-3742.
79. Talora, C.; Sgroi, D.C.; Crum, C.P.; Dotto, G.P. Specific downmodulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation.Genes Dev., 2002, 16(17), 2252-2263.
80. Kuncharin, Y.; Sangphech, N.; Kueanjinda, P.; Bhattarakosol, P.; Palaga, T. MAML1 regulates cell viability via the NF-kappaB pathway in cervical cancer cell lines. Exp. Cell Res., 2011, 317(13), 1830-1840.
81. Agrawal, N.; Frederick, M.J.; Pickering, C.R.; Bettegowda, C.; Chang, K.; Li, R.J.; Fakhry, C.; Xie, T.X.; Zhang, J.; Wang, J.; Zhang, N.; El-Naggar, A.K.; Jasser, S.A.; Weinstein, J.N.; Trevino, L.; Drummond, J.A.; Muzny, D.M.; Wu, Y.; Wood, L.D.; Hruban, R.H.; Westra, W.H.; Koch,W.M.; Califano, J.A.; Gibbs, R.A.; Sidransky, D.; Vogelstein, B.; Velculescu, V.E.; Papadopoulos, N.; Wheeler, D.A.; Kinzler K.W.; Myers J.N. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science, 2011, 333(6046), 1154-1157.
82. Weijzen, S.; Zlobin, A.; Braid, M.; Miele, L.; Kast, W.M. HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J. Cell. Physiol., 2003, 194(3), 356-362.
83. Rangarajan, A.; Syal, R.; Selvarajah, S.; Chakrabarti, O.; Sarin, A.; Krishna, S. Activated Notch1 signaling cooperates with papillomavirus oncogenes in transformation and generates resistance to apoptosis on matrix withdrawal through PKB/Akt. Virology, 2001, 286(1), 23-30.
84. Tan, M.J.; White, E.A.; Sowa, M.E.; Harper, J.W.; Aster J.C.; Howley, P.M. Cutaneous beta-human papillomavirus E6 proteins bind Mastermind-like coactivators and repress Notch signaling. Proc. Natl. Acad. Sci. USA, 2012, 109(23), E1473-E1480.
85. Meyers, J.M.; Spangle, J.M.; Munger, K. The Human Papillomavirus Type 8 E6 Protein Interferes with NOTCH Activation during Keratinocyte Differentiation. J. Virol., 2013, 87(8), 4762-4767.
86. Maliekal, T.T.; Bajaj, J.; Giri, V.; Subramanyam, D.; Krishna, S. The role of Notch signaling in human cervical cancer: implications for solid tumors. Oncogene, 2008, 27(38), 5110-5114.
87. Ramdass, B.; Maliekal, T.T.; Lakshmi, S.; Rehman, M.; Rema, P.; Nair, P.; Mukherjee, G.; Reddy, B.K.; Krishna, S.; Radhakrishna, P.M. Coexpression of Notch1 and NF-kappaB signaling pathway components in human cervical cancer progression. Gynecol. Oncol., 2007, 104(2), 352-361.
88. Veeraraghavalu, K.; Subbaiah, V.K.; Srivastava, S.; Chakrabarti, O.; Syal, R.; Krishna, S. Complementation of human papillomavirus type 16 E6 and E7 by Jagged1-specific Notch1-phosphatidylinositol 3-kinase signaling involves pleiotropic oncogenic functions independent of CBF1;Su(H);Lag-1 activation. J. Virol., 2005, 79(12), 7889-7898.
89. Soond, D.R.; Slack, E.C.; Garden, O.A.; Patton, D.T.; Okkenhaug, K. Does the PI3K pathway promote or antagonize regulatory T cell development and function? Front. Immunol., 2012, 3, 244.
90. Henken, F.E.; Banerjee, N.S.; Snijders, P.J.; Meijer, C.J.; De-Castro, A.J.; Rosl, F.; Broker, T.R.; Chow L.T.; Steenbergen, R.D. The functional role of Notch signaling in HPV-mediated transformation is dose-dependent and linked to AP-1 alterations. Cell Oncol., 2012, 35(2), 77-84.
91. Elyaman, W.; Bassil, R.; Bradshaw, E. M.; Orent, W.; Lahoud, Y.; Zhu, B.; Radtke, F.; Yagita, H.; Khoury, S.J. Notch receptors and Smad3 signaling cooperate in the induction of interleukin-9-producing T cells. Immunity, 2012, 36(4), 623-634.
92. Cicchi, R.; Massi, D.; Sestini, S.; Carli, P.; De, G.V.; Lotti, T.; Pavone, F.S. Multidimensional non-linear laser imaging of Basal Cell Carcinoma.Optics Express., 2007, 15(16), 10135-10148.
93. Veeraraghavalu, K.; Pett, M.; Kumar, R.V.; Nair, P.; Rangarajan, A.; Stanley, M.A.; Krishna, S. Papillomavirus-mediated neoplastic progression is associated with reciprocal changes in JAGGED1 and manic fringe expression linked to notch activation. J. Virol., 2004, 78(16), 8687-8700.
94. Lathion, S.; Schaper, J.; Beard, P.; Raj, K. Notch1 can contribute to viral-induced transformation of primary human keratinocytes. Cancer Res., 2003, 63(24), 8687-8694.
95. Nair, P.; Somasundaram, K.; Krishna, S. Activated Notch1 inhibits p53-induced apoptosis and sustains transformation by human papillomavirus type 16 E6 and E7 oncogenes through a PI3KPKB/ Akt-dependent pathway. J. Virol., 2003, 77(12), 7106-7112.
96. Brimer, N.; Lyons, C.; Wallberg, A. E.; Vande Pol, S.B. Cutaneous papillomavirus E6 oncoproteins associate with MAML1 to repress transactivation and NOTCH signaling.Oncogene, 2012, 31(43), 4639-4646.
97. de Wilde, J.; De-Castro Arce, J.; Snijders, P.J.; Meijer, C.J.; Rosl, F.; Steenbergen R.D. Alterations in AP-1 and AP-1 regulatory genes during HPV-induced carcinogenesis. Cell Oncol., 2008, 30(1), 77-87.
98. Prusty, B.K.; Das, B.C. Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int. J. Cancer, 2005, 113(6), 951-960.
99. Hancock, M.K.; Kopp, L.; Bi, K. High-throughput screening compatible cell-based assay for interrogating activated notch signaling. Assay Drug Dev. Technol., 2009, 7(1), 68-79.
100. Ma, Y.Y.; Wei, S. J.; Lin, Y.C.; Lung, J.C.; Chang, T.C.; Whang-Peng, J.; Liu, M.; Yang, D.M.; Yang W.K.; Shen, C.Y. PIK3CA as an oncogene in cervical cancer. Oncogene, 2000, 19(23), 2739-2744.
101. Goto, T.; Takano, M.; Sakamoto, M.; Kondo, A.; Hirata, J.; Kita, T.; Tsuda, H.; Tenjin, Y.; Kikuchi, Y. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. Oncol. Rep., 2006, 15(5), 1265-1271.
102. Goto, T.; Takano, M.; Sasa, H.; Tsuda, H.; Yamauchi, K.; Kikuchi, Y. Clinical significance of immunocytochemistry for PIK3CA as a carcinogenesis-related marker on liquid-based cytology in cervical intraepithelial neoplasia. Oncol. Rep., 2006, 15(2), 387-391.
103. Cui, B.; Zheng, B.; Zhang, X.; Stendahl, U.; Andersson, S.; Wallin, K.L. Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. Int. J. Oncol., 2009, 34(2), 409-416.
104. Lee, C.M.; Fuhrman, C.B.; Planelles, V.; Peltier, M.R.; Gaffney, D.K.; Soisson, A.P.; Dodson, M.K.; Tolley, H.D.; Green, C.L.; Zempolich, K.A. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. Clin. Cancer Res., 2006, 12(1), 250-256.
105. Henken, F.E.; Banerjee, N.S.; Snijders, P.J.; Meijer, C.J.; De-Castro, A.J.; Rosl, F.; Broker, T.R.; Chow, L.T.; Steenbergen, R.D. PIK3CA-mediated PI3-kinase signalling is essential for HPVinduced transformation in vitro. Mol. Cancer, 2011, 10, 71-81.
106. Janku, F.; Wheler, J.J.; Westin, S.N.; Moulder, S.L.; Naing, A.; Tsimberidou, A.M.; Fu, S.; Falchook, G.S.; Hong, D.S.; Garrido-Laguna, I.; Luthra, R.; Lee, J.J.; Lu, K.H.; Kurzrock, R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J. Clin. Oncol., 2012, 30(8), 777-782.
107. Geiger, T.; Levitzki, A. Loss of robustness and addiction to IGF1 during early keratinocyte transformation by human Papilloma virus 16. PloS One, 2007, 2(7), e605.
108. Janku, F.; Wheler, J.J.; Westin, S.N.; Moulder, S.L.; Naing, A.; Tsimberidou, A.M.; Fu, S.; Falchook, G.S.; Hong, D.S.; Garrido-Laguna, I.; Luthra, R.; Lee, J.J.; Lu, K.H.; Kurzrock, R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PloS One, 2011, 6(7), e22769.
109. Bertelsen, B.I.; Steine, S.J.; Sandvei, R.; Molven, A.; Laerum, O.D. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. International journal of cancer. Int. J. Cancer, 2006, 118(8), 1877-1883.
110. Robertson, L.K.; Mireau, L.R.; Ostergaard, H.L. A role for phosphatidylinositol 3-kinase in TCR-stimulated ERK activation leading to paxillin phosphorylation and CTL degranulation. J. Immunol., 2005, 175(12), 8138-8145.
111. Gadgeel, S.M.; Lew, D.L.; Synold, T.W.; Lorusso, P.; Chung, V.; Christensen, S.D.; Smith, D.C.; Kingsbury, L.; Hoering, A.; Kurzrock, R. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother. Pharmacol., 2013, 72(5), 1089-1096.
112. Renshaw, J.; Taylor, K.R.; Bishop, R.; Valenti, M.; De, H.B.A.; Gowan, S.; Eccles, S.A.; Ruddle, R.R.; Johnson, L.D.; Raynaud, F.I.; Selfe, J.L.; Thway, K.; Pietsch, T.; Pearson A.D.; Shipley, J. Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo. Clin. Cancer Res., 2013, 19(21), 5940-5951.
113. Janku, F.; Wheler, J.J.; Naing, A.; Stepanek, V.M.; Falchook, G.S.; Fu, S.; Garrido-Laguna, I.; Tsimberidou, A.M.; Piha-Paul, S.A.; Moulder, S.L.; Lee, J.J.; Luthra, R.; Hong D.S.; Kurzrock, R. PIK3CA mutations in advanced cancers: characteristics and outcomes.Oncotarget, 2012, 3(12), 1566-1575.
114. Shepherd, C.; Banerjee, L.; Cheung, C. W.; Mansour, M. R.; Jenkinson, S.; Gale, R. E.; Khwaja, A. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. Leukemia, 2013, 27(3), 650-660.
115. Keysar, S.B.; Astling, D.P.; Anderson, R.T.; Vogler, B.W.; Bowles, D.W.; Morton, J.J.; Paylor, J.J.; Glogowska, M.J.; Le, P.N.; Eagles-Soukup, J.R.; Kako, S.L.; Takimoto, S.M.; Sehrt, D.B.; Umpierrez, A.; Pittman, M.A.; Macfadden, S.M.; Helber, R.M.; Peterson, S.; Hausman, D.F.; Said, S.; Leem, T.H.; Goddard, J.A.; Arcaroli, J.J.; Messersmith, W.A.; Robinson, W.A.; Hirsch, F.; Varella-Garcia, M.; Raben, D.; Wang, X.J.; Song, J.I.; Tan, A.C.; Jimeno, A. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol. Oncol., 2013, 7(4), 776-790.
116. Hong, D.S.; Bowles, D.W.; Falchook, G.S.; Messersmith, W.A.; George, G.C.; O'Bryant, C.L.; Vo, A.C.; Klucher, K.; Herbst, R.S.; Eckhardt, S.G.; Peterson, S.; Hausman, D.F.; Kurzrock R.; Jimeno, A. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin. Cancer Res., 2012, 18(15), 4173-4182.
117. Bowles, D.W.; Ma, W.W.; Senzer, N.; Brahmer, J.R.; Adjei, A.A.; Davies, M.; Lazar, A.J.; Vo, A.; Peterson, S.; Walker, L.; Hausman, D.; Rudin, C.M.; Jimeno, A. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumors. Br. J. Cancer, 2013, 109(5), 1085-1092.
118. Chen, J. Multiple signal pathways in obesity-associated cancer. Obes. Rev., 2011, 12(12), 1063-1070.
119. Anderson, R.T.; Keysar, S.B.; Bowles, D.W.; Glogowska, M.J.; Astling, D.P.; Morton, J.J.; Le, P.; Umpierrez, A.; Eagles-Soukup, J.; Gan, G.N.; Vogler, B.W.; Sehrt, D.; Takimoto, S.M.; Aisner, D.L.; Wilhelm, F.; Frederick, B.A.; Varella-Garcia, M.; Tan, A.C.; Jimeno, A. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.Mol. Cancer Therap., 2013, 12(10), 1994-2005.
120. Wu, J.; Chen, C.; Zhao, K.N. Phosphatidylinositol 3-kinase signaling as a therapeutic target for cervical cancer.Curr. Cancer Drug Targets, 2013, 13(2), 143-156.